The integration of palliative care and oncology: the evidence.

Cancer care and palliative care each require a complex multi- and interdisciplinary approach to maximize the care of people with cancer. Recommendations for cancer treatment should both relieve the symptoms of cancer and prevent and treat side effects of anticancer therapy. Unrelieved symptoms not only contribute to worse quality of life but also can reduce a patient's ability to tolerate cancer therapy and may have a negative impact on survival. Consistent integration of palliative care practices into standard oncology care is needed across the trajectory of the cancer experience. This article will review the overlap between palliative care and oncology and discuss the available evidence that true integration of palliative and oncology care provides patients with optimal oncology care.

[1]  J. Temel,et al.  Does palliative care improve outcomes for patients with incurable illness? A review of the evidence. , 2011, The journal of supportive oncology.

[2]  I. Higginson,et al.  What Is the Evidence That Palliative Care Teams Improve Outcomes for Cancer Patients and Their Families? , 2010, Cancer journal.

[3]  Alona Muzikansky,et al.  Early palliative care for patients with metastatic non-small-cell lung cancer. , 2010, The New England journal of medicine.

[4]  I. Tannock,et al.  Effectiveness of specialized palliative care: a systematic review. , 2008, JAMA.

[5]  J. V. Von Roenn,et al.  A study of oncology fellows' training in end-of-life care. , 2007, The journal of supportive oncology.

[6]  A. Bezjak,et al.  Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Kris,et al.  Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[9]  C. Gunten.  Secondary and tertiary palliative care in US hospitals. , 2002 .

[10]  C. Gridelli.  The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. , 2001, The oncologist.

[11]  M. Ranson,et al.  Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[12]  R. Stephens,et al.  Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome , 2000, British Journal of Cancer.

[13]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Roszkowski,et al.  A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). , 2000, Lung cancer.

[15]  M. Ranson,et al.  Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. , 1995 .

[16]  M. Cullen,et al.  Trials with mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. , 1995, Lung cancer.

[17]  P. Ellis,et al.  Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. , 1995, British Journal of Cancer.

[18]  David E Morris,et al.  Chemotherapeutic management of stage IV non-small cell lung cancer. , 2003, Chest.